Results 181 to 190 of about 380,167 (333)

Sleep disorders in renal patients: a comparative analysis of dialysis and post-renal transplant outcomes. [PDF]

open access: yesSci Rep
Alharbi T   +9 more
europepmc   +1 more source

Robotic renal transplantation: Current status

open access: gold, 2014
Anil K. Sood   +5 more
openalex   +1 more source

A Subset of Pro‐inflammatory CXCL10+ LILRB2+ Macrophages Derives From Recipient Monocytes and Drives Renal Allograft Rejection

open access: yesAdvanced Science, EarlyView.
This study uncovers a recipient‐derived monocyte‐to‐macrophage trajectory that drives inflammation during kidney transplant rejection. Using over 150 000 single‐cell profiles and more than 850 biopsies, the authors identify CXCL10+ macrophages as key predictors of graft loss.
Alexis Varin   +16 more
wiley   +1 more source

Impact of deceased donor acute kidney injury (AKI) on renal transplant outcomes. [PDF]

open access: yesSurg Open Sci
Nozdrin M   +6 more
europepmc   +1 more source

Co‐Treatment With rhBMP‐2 and Rapamycin Modulates Osteogenesis–Adipogenesis Balance to Enhance Aged Bone Regeneration

open access: yesAdvanced Science, EarlyView.
This study demonstrates that the imbalance between osteogenic and adipogenic differentiation in senescent BMSCs, leading to excessive adipocyte accumulation, which subsequently impairs bone regeneration in aged mice. To address this pathological dysregulation, a novel energy‐supplying hydrogel system (PBR) has been developed to restore balanced ...
Zirui He   +7 more
wiley   +1 more source

Barriers to Renal Transplant in Pakistan. [PDF]

open access: yesCureus
Afzal A   +8 more
europepmc   +1 more source

Iatrogenic Alterations of Immunologic Surveillance in Man and Their Influence on Malignancy [PDF]

open access: yes, 1971
Agosin M.   +85 more
core   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy